KEN vs NRIX Comparison

Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented, businesses. The company's operating segments include OPC; CPV Group; and ZIM. It generates maximum revenue from the OPC segment. OPC operates in the Israeli electricity generation sector, including initiating, developing, constructing, and operating power plants and selling and supplying electricity. Geographically, it derives a majority of its revenue from Israel.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.